{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:15:02Z","timestamp":1788585302158,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["canadianjournalofophthalmology.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jcjo.2026.04.003","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:29:39Z","timestamp":1785900579000},"page":"1079-1087","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intraocular pressure-lowering effects of tetrahydrocannabinol drugs: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0571-2894","authenticated-orcid":false,"given":"Thanansayan","family":"Dhivagaran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad","family":"Butt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8488-2060","authenticated-orcid":false,"given":"David","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2026.04.003_bib0001","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/bjo.2005.081224","article-title":"The number of people with glaucoma worldwide in 2010 and 2020","volume":"90","author":"Quigley","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.04.003_bib0002","doi-asserted-by":"crossref","first-page":"P112","DOI":"10.1016\/j.ophtha.2015.10.055","article-title":"Primary open-angle glaucoma suspect Preferred Practice PatternR Guidelines","volume":"123","author":"Prum","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2026.04.003_bib0003","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0002-9394(00)00538-9","article-title":"The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators","volume":"130","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.04.003_bib0004","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/tcrm.2006.2.2.193","article-title":"The management of glaucoma and intraocular hypertension: current approaches and recent advances","volume":"2","author":"Noecker","year":"2006","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.jcjo.2026.04.003_bib0005","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/cpt.1797","article-title":"The effect of orally administered dronabinol on optic nerve head blood flow in healthy subjects\u2014A randomized clinical trial","volume":"108","author":"Hommer","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jcjo.2026.04.003_bib0006","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1097\/00007611-197708000-00016","article-title":"Effect of delta-9-tetrahydrocannabinol on intraocular pressure in humans","volume":"70","author":"Cooler","year":"1977","journal-title":"South Med J"},{"key":"10.1016\/j.jcjo.2026.04.003_bib0007","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/archopht.1982.01030030267006","article-title":"Ocular effects of topical administration of delta 9-tetrahydrocannabinol in man","volume":"100","author":"Green","year":"1982","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.04.003_bib0008","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1001\/archopht.1983.01040010591012","article-title":"Multiple-drop study of topically applied 1% delta 9-tetrahydrocannabinol in human eyes","volume":"101","author":"Jay","year":"1983","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.04.003_bib0009","first-page":"215","article-title":"Delta-9-tetrahydrocannabinol (THC) in the treatment of end-stage open-angle glaucoma","volume":"100","author":"Flach","year":"2002","journal-title":"Trans Am Ophthalmol Soc"},{"key":"10.1016\/j.jcjo.2026.04.003_bib0010","article-title":"The relationship between plasma tetrahydrocannabinol levels and intraocular pressure in healthy adult subjects","volume":"8","author":"Mosaed","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jcjo.2026.04.003_bib0011","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1167\/iovs.18-24838","article-title":"\u03949-Tetrahydrocannabinol and cannabidiol differentially regulate intraocular pressure","volume":"59","author":"Miller","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jcjo.2026.04.003_bib0012","first-page":"102","article-title":"Interaction of adrenergic antagonists with prostaglandin E2 and tetrahydrocannabinol in the eye","volume":"15","author":"Green","year":"1976","journal-title":"Invest Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.04.003_bib0013","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/9364091","article-title":"The endocannabinoid system as a therapeutic target in glaucoma","volume":"2016","author":"Cairns","year":"2016","journal-title":"Neural Plast"},{"key":"10.1016\/j.jcjo.2026.04.003_bib0014","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3390\/ph13090231","article-title":"Pharmacokinetic comparison of three different administration routes for topotecan hydrochloride in rats","volume":"13","author":"Jeong","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jcjo.2026.04.003_bib0015","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3810\/psm.2013.05.2016","article-title":"Effectiveness and safety of topical versus oral nonsteroidal anti-inflammatory drugs: a comprehensive review","volume":"41","author":"Klinge","year":"2013","journal-title":"Phys Sportsmed"},{"key":"10.1016\/j.jcjo.2026.04.003_bib0016","series-title":"StatPearls","article-title":"First-pass effect","author":"Herman","year":"2025"},{"key":"10.1016\/j.jcjo.2026.04.003_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.618411","article-title":"Advances in oral drug delivery","volume":"12","author":"Alqahtani","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcjo.2026.04.003_bib0018","series-title":"StatPearls","article-title":"Medication routes of administration","author":"Kim","year":"2025"},{"key":"10.1016\/j.jcjo.2026.04.003_bib0019","unstructured":"College of Pharmicists of Manitoba . Changes to health Canada\u2019s cannabis authorization process medical purposes.https:\/\/cpsm.mb.ca\/news\/changes-to-health-canadas-cannabis-authorization-process-medical-purposes. Accessed July 27, 2025."},{"key":"10.1016\/j.jcjo.2026.04.003_bib0020","series-title":"Controlled Drugs and Substances Act","year":"1996"},{"key":"10.1016\/j.jcjo.2026.04.003_bib0021","series-title":"Regulations amending certain regulations concerning cannabis (streamlining of requirements): SOR\/2025-43","year":"2025"},{"key":"10.1016\/j.jcjo.2026.04.003_bib0022","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1056\/NEJM199810293391808","article-title":"Medical management of glaucoma","volume":"339","author":"Alward","year":"1998","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jcjo.2026.04.003_bib0023","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.2147\/OPTH.S87988","article-title":"The intraocular pressure-lowering properties of intravenous paracetamol","author":"Van Den Heever","year":"2016","journal-title":"Clin Ophthalmol"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000841822600150X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000841822600150X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:27:07Z","timestamp":1788582427000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000841822600150X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S000841822600150X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2026.04.003","relation":{},"ISSN":["0008-4182"],"issn-type":[{"value":"0008-4182","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intraocular pressure-lowering effects of tetrahydrocannabinol drugs: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2026.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of Canadian Ophthalmological Society.","name":"copyright","label":"Copyright"}]}}